Abstract: The present invention is directed to a storage-stable formulation of long-chain RNA. In particular, the invention concerns a dry powder composition comprising a long-chain RNA molecule. The present invention is furthermore directed to methods for preparing a dry powder composition comprising a long-chain RNA molecule by spray-drying. The invention further concerns the use of such a dry powder composition comprising a long-chain RNA molecule in the preparation of pharmaceutical compositions and vaccines, to a method of treating or preventing a disorder or a disease, to first and second medical uses of such a dry powder composition comprising a long-chain RNA molecule and to kits, particularly to kits of parts, comprising such a dry powder composition comprising a long-chain RNA molecule.

Abstract: The invention provides a vaccine composition comprising a flavivirus peptide comprising one or more CD8+ T cell C1 epitopes, wherein the peptide is attached to a nanoparticle.

Abstract: The present invention is directed to a depot composition for sustained release delivery of buprenorphine with enhanced stability and bioavailability. The composition is an injectable, low viscosity liquid and can form a depot in situ capable of delivering therapeutic level of buprenorphine over a period of time from one week to 3 months.

Abstract: Described herein are methods of reducing the risk of recurrence of bacterial vaginosis by intravaginal administration of compositions comprising L-lactic acid, polymer thickener, and preservative.

Abstract: Compositions comprising unseparated amnion/chorion derived from the placenta and methods of preparing and using those compositions are provided. Washing or preservation of placental tissue according to the methods of the disclosure may allow for one or more benefits such as more efficient removal of blood remnants, retention of wound healing and tissue regeneration components, better handling characteristics, increased absorption potential, or improved healing capacity. The present invention also includes methods of healing a wound of the skin, eye, nerve, tendon, or dura comprising applying the compositions of the invention to the wound.

Abstract: The present disclosure provides methods of treating defects such as wrinkles or scars via a subdermal injection of placental tissue components. It also provides placental tissue compositions maintained within the barrel of a syringe, which may be for use in treating such defects.

Abstract: Techniques are described for extracting key values from a document without having to rely on finding corresponding labels for the target keys within the extracted text of the document. Further the techniques do not rely on knowledge of the correlation between (a) the location of labels within a document, and (b) the location of the key values that correspond to the labels. Key values are extracted from a document by, identifying candidate values within the document, establishing “joint-candidate” sets from those candidate values, and using a trained machine learning mechanism to score each joint-candidate set of values. The highest scoring joint-candidate set is deemed to reflect the correct mapping of candidate values to target keys for the document.

Abstract: The present invention relates to artificial tear compositions and ophthalmic compositions suitable for drug delivery. In one embodiment of the present invention, the compositions comprise a galactomannan polymer such as guar or hydroxypropyl guar, hyaluronic acid, and a cis-diol such as sorbitol. In a preferred embodiment, the to compositions also comprise a borate compound.

Abstract: Embodiments described herein relate to restorative solutions for segmental peripheral nerve (PN) defects using allografted PNs for stimulating PN repair. More specifically, embodiments described herein provide for localized immunosuppression (LIS) surrounding PN allografts as an alternative to systemically suppressing a patient's entire immune system. Methods include localized release of immunosuppressive (ISV) agents are contemplated in one embodiment. Methods also include localized application of immunosuppressive (ISV) regulatory T-cells (Tregs) and/or mesenchymal stomal cells in other embodiments. Hydrogel carrier materials are also described herein.

Abstract: A pro-apoptotic solid dispersion comprises, in essentially non-crystalline form, a Bcl-2 family protein inhibitory compound of Formula I as defined herein, dispersed in a solid matrix that comprises (a) a pharmaceutically acceptable water-soluble polymeric carrier and (b) a pharmaceutically acceptable surfactant. A process for preparing such a solid dispersion comprises subjecting to elevated temperature the compound of Formula I, the water-soluble polymeric carrier and the surfactant, to provide an extrudable semi-solid mixture; extruding the semi-solid mixture; and cooling the resulting extrudate to provide a solid matrix comprising the polymeric carrier and the surfactant and having the compound dispersed in essentially non-crystalline form therein. The solid dispersion is suitable for oral administration to a subject in need thereof for treatment of a disease characterized by overexpression of one or more anti-apoptotic Bcl-2 family proteins, for example cancer or an immune or autoimmune disease.

Abstract: A patch-type sensor module is provided. A patch-type sensor module according to one embodiment of the present invention comprises: a power supply unit electrically connected with a flexible circuit board; a sensing unit which is mounted on the flexible circuit board and includes a temperature sensor for measuring a user's body temperature; a communication unit which allows power to be supplied using a wake-up function, wherein a pairing with an external communication module is concurrently established when power is supplied, and information measured through the sensing unit is then transmitted to the external communication module; a control unit for controlling operations of the power supply unit, the sensing unit, and the communication unit; and a protection member for preventing the flexible circuit board, the power supply unit, the sensing unit, the communication unit, and the control unit from being exposed to the outside.

Abstract: A build-plate with integrally-formed spinal implant constructs and a method used in forming spinal implant constructs on the build plate and machining the spinal implant constructs formed on the build plate to manufacture spinal implants is provided. The spinal implant constructs can be formed via additive manufacturing processes by adding material to an upper surface of the build plate, and then the spinal implant constructs can be subjected to subtractive manufacturing processes to form the spinal implants.

Abstract: The invention provides methods for preventing, ameliorating and treating the acute and chronic forms of graft-versus-host disease (GVHD) by using Cannabidiol compositions.

Abstract: The invention provides systems and methods for increased clinical efficacy of rifabutin against A. baumannii. The invention takes advantage of the discovery of a ferric-coprogen (FhuE) receptor that is responsible for the uptake of rifabutin into A. baumannii cells. Methods preferably include obtaining a sample from a patient suspected of having an infection; performing a test on the sample to identify an infection of A. baumannii in the patient; and providing a formulation of rifabutin for treating the patient that, when administered to the patient, maximizes a resultant AUC and/or Cmax. The method may include administering the formulation of rifabutin to the patient. Preferably the formulation is delivered to the patient, e.g., by intravenous injection and results in a Cmax is that greater than about 2 mg/L and optionally less than about 50 mg/L.

Abstract: The invention relates to a poly(n-butyl cyanoacrylate) nanoparticle with dual modifications, a drug delivery system comprising the nanoparticle, and a method for preparing the nanoparticle or the drug delivery system. The nanoparticle is modified with a first modifier and a second modifier on the surface, the first modifier is a hydrophilic polymer, and the second modifier is an amino acid and/or a lipid. The invention further relates to a use of the nanoparticle in promoting drug penetration across the blood brain barrier in a subject.

Abstract: A skincare rejuvenation composition, adapted at least for tactile use, consists essentially of a skincare rejuvenation ingredient, a skin exfoliation ingredient, an acidity balancing ingredient, a sunscreen composition and an emulsifier. The skincare rejuvenation ingredient has a first weight percentage, the skin exfoliation ingredient has a second weight percentage, and the acidity balancing ingredient has a third weight percentage, whereby each of the first weight percentage, the second weight percentage, and the third weight percentage are substantially equal. As an example, the skincare rejuvenation ingredient may be retinol, the skin exfoliation ingredient may be glycolic acid, and the acidity balancing ingredient may be hyaluronic acid.

Abstract: A photocatalyst can be regenerated with increasing efficiency, turnover number and turnover frequency in the presence of air by irradiating the photocatalyst with a first range of wavelengths of light that excite the photocatalyst to an intermediate and irradiating the intermediate with a second range of wavelengths of light that turns the intermediate to the photocatalyst.

Abstract: The invention provides formulations containing highly concentrated solutions of rifabutin and methods of making such formulations. The invention also provides methods of using such formulations to treat a bacterial infection in a subject.

Abstract: The invention relates to oil-in-water emulsion in which specific oils (e.g., lauric oils) are used in the oil phase while surprisingly maintaining excellent transparency. In one aspect, said emulsions comprise fatty acid in oil phase. The invention comprises an energy efficient process for making said fatty acid containing transparent nanoemulsions.

Abstract: Disclosed are pharmaceutical compositions comprising three antiviral compounds. In particular, the pharmaceutical compositions comprise an effective amount of velpatasvir, an effective amount of sofosbuvir, and an effective amount of voxilaprevir. Also disclosed are methods of use for the pharmaceutical composition.

Abstract: Disclosed herein are self-emulsifying compositions and formulations of Dimdolylmethane (“DIM”) and certain derivatives of DIM, their uses and methods of making. In particular, the disclosed compositions comprise a DIM-related indole as an active agent and a carrier, wherein the carrier comprises a solvent, one or more surfactants with an HLB of greater than 7, and one or more co-surfactants with an HLB equal to or less than 7. In certain aspects of the invention, the compositions disclosed herein show improved bioavailability.

Abstract: The present disclosure relates to a cosmetic composition for blocking fine dust. The composition according to the present disclosure can fundamentally prevent problems due to fine dust by reducing the attachment rate of fine dust attached to skin.

Abstract: The invention provides a hydrogen sulfide releasing polymer compound having a polysaccharide backbone, wherein the compound has at least two substructures, and wherein said substructures are capable of releasing hydrogen sulfide by thiol activation as well as uses thereof. Additionally, a method of treatment and prevention of a skin condition, an ocular disease or osteoarthritis is provided.

Abstract: The present invention relates to coated silk films. Further, the present invention relates to pharmaceutical or cosmetic compositions comprising the coated silk films. Furthermore, the present invention relates to coated silk films or pharmaceutical compositions comprising the coated silk films for use in medicine. In addition, the present invention relates to methods of producing the coated silk films.

Abstract: Disclosed herein are immediate release oral dosage forms that contain abuse-deterrent and abuse-resistant features. In particular, the disclosed dosage forms can provide deterrence of abuse by ingestion of multiple individual doses. The disclosed dosage forms can likewise provide protection from overdose in the event of accidental or intentional ingestion of multiple individual doses. The dosage forms may also exhibit abuse resistant properties when physically manipulated, and also when physically manipulated and then administered in a manner not consistent with oral dosing. The dosage forms may also exhibit abuse resistant properties when administered in a manner intended to result in administration of the esketamine in a higher than therapeutic dose.

Abstract: This invention provides core shell silica particles, wherein each core shell silica particle comprises a silica core, and a surface of the silica core etched with group I metal silicate. These core shell silica particles have high surface charge density and anti-bacterial activity. Also provided are compositions comprising core shell silica particles, process of making the core shell silica particles and methods of reducing or inhibiting bacterial activity by administering the core shell silica particles or compositions thereof.

Abstract: Disclosed are various embodiments of lipid multiparticulate compositions comprising at least one active agent, a low flow point excipient, and a high flow point excipient.

Abstract: The present invention provides a device, method, and program for detection of a biomarker candidate that may be used in a diagnosis of a pre-disease state indicating a transition from a healthy state to a disease state. Biological samples are collected from a subject to be measured at different times. Statistical data is obtained by aggregating measurement data obtained in measurement on collected biological samples. Thereafter, a process of obtaining high-throughput data (s1), a process of choosing differential biological molecules (s2), a process of clustering (s3), a process of choosing a DNB candidate (s4), and a process of identifying a DNB by significance analysis (s5) are carried out.

Abstract: The invention relates to balloon coatings and their use in delivering drugs via a drug-eluting balloon. The delivery can be, e.g., to a vessel wall.

Abstract: The present disclosure provides, among other things, compositions and methods useful for inhibiting biofilm-forming bacteria. For example, the compositions and methods described herein can be used to inhibit the proliferation, viability, and/or biofilm-forming activity, of biofilm-forming bacteria.

Abstract: The invention provides a liquid-dispersible powder comprising nanoscale grains of matrix embedded with one or more isolated nanoparticles and a composition for the magnetic nanoparticle hyperthermia (MNH) treatment of tumours comprising nanoscale grains of matrix material containing one or more isolated nanoparticles. The invention also provides a method of production of a liquid-dispersible powder described herein, the method comprising the steps of providing nanoparticles prepared under ultra-high vacuum (UHV) gas phase conditions; co-depositing the nanoparticles within a matrix material under UHV gas phase conditions; and grinding the film to a fine powder comprising grains of groups of matrix material isolated nanoparticles.

Abstract: Topical pharmaceutical compositions include tazarotene or a pharmaceutically acceptable salt of tazarotenic acid and an oil-in-water emulsion vehicle that forms a lotion. The compositions are used to treat skin diseases, such as acne vulgaris.

Abstract: A pharmaceutical composition of micronutrients were tried to improve cognitive brain function, brain health and nervous system functions. Combination consisting of Avena sativa (green oat straw extract), Coenzyme Q10, NAD+, American Ginseng, and Pyrroloquinoline quinone in physiological dose range shows multiple simultaneous positive effects in supporting key functions in cells building our nervous system essential for optimum mental and/or cognitive health including protecting nervous system cells against various damaging factors, increasing ATP production, stimulating mitochondria biogenesis, increasing mitochondrial membrane potential, increasing mitochondrial functions (Complex I activity), exhibiting anti-inflammatory capacity and increased BDNF secretion.

Abstract: A pharmaceutical composition of micronutrients were tried to improve brain health and nervous system functions. Combination of L-theanine, Rhodiola rosea, Acetyl L-Carnitine (ALCAR), Bacopa monnieri, Mucuna pruriens, NAD+, Rose hips extract (trans-tiliroside), American Ginseng, Pyrroloquinoline quinone, Gotu Kola in physiological dose range shows multiple simultaneous positive effects in supporting key functions in cells building our nervous system essential for optimum mental and/or cognitive health including protecting nervous system cells against various damaging factors, increasing ATP production, stimulating mitochondria biogenesis, increasing mitochondrial membrane potential, increasing mitochondrial functions (Complex I activity), exhibiting anti-inflammatory capacity and increased BDNF secretion.

Abstract: The present invention is directed to methods and compositions for the treatment of diverticulosis. It is more specifically directed to compositions including L-glutamine, its salts, or its derivatives, and uses of such compositions in the treatment of diverticulosis. In a method aspect, the present invention provides a method of treating diverticulosis. The method includes ingestion of 0.05 g/kg body weight to 10.0 g/kg body weight of L-glutamine, an L-glutamine salt or an L-glutamine derivative per day by a person who has diverticulosis.

Abstract: Ultra-small Lipid Structures (USLS) with an average mean particle diameter of less than 100 nm are made using a single step process by diluting a hydro-organic solution containing lipids and passenger compounds. These particles are capable of sequestering the passenger molecules and self-assemble in a single process step into USLS. The USLS have applications in, for example, agricultural, cosmetics, pharmaceutical and food and beverage industries.

Abstract: Disclosed is a method of producing high-concentration collagen for use as a medical material, including: washing tissue of a mammal; subjecting the washed tissue to crushing and immersion in ethyl alcohol; subjecting the tissue to enzymatic treatment with stirring in purified water containing phosphoric acid and pepsin; adding sodium chloride to the collagen subjected to enzymatic treatment, performing stirring, and aggregating collagen; dissolving the aggregated collagen in purified water to give a collagen solution, which is then filtered using a filter and concentrated by removing the pepsin, low-molecular-weight material, and sodium chloride from the collagen solution using a tangential flow filtration device; subjecting the concentrated collagen to sterile filtration, aggregating the collagen using a pH solution in a neutralization tank, and concentrating the collagen by removing a non-aggregated solution; and concentrating the concentrated collagen using a centrifuge and stirring the concentrated collag

Abstract: A gel composition that forms a three dimensional gel microenvironment that is formed of an adhesive protein, a maleimide-functionalized poly alkylene oxide, a linking agent and a nanoparticle, the components forming an interpenetrating network that exhibits improved mechanical and biochemical properties, as well as creates a favorable microenvironment for cellular growth and proliferation. The gel composition also creates a favorable microenvironment for testing various agents on normal or diseased cells, including chemotherapeutic agents on cancer cells or other diseased cells.

Abstract: The present invention provides dimethyl fumarate (DMF) particles and methods of preparing the DMF particles. Also provided is DMF coated particles comprising DMF particles coated with an enteric coating. The invention also provides various dosage forms and methods of treating a disease or disorder (e.g., multiple sclerosis).

Abstract: The present disclosure relates to pharmaceutical compositions containing phenytoin or phenytoin sodium for use in topical pain relief. Use of the pharmaceutical composition of the disclosure reduces peripheral neuropathic pain. The topical pharmaceutical compositions of the disclosure containing phenytoin or phenytoin sodium, surprisingly reduce peripheral neuropathic pain considerably, especially and preferably in the conditions, characterized by a low to moderate grade of peripheral neurogenic inflammation, such as small fiber neuropathy, diabetic neuropathy, chronic idiopathic axonal polyneuropathy, post-herpetic neuralgia, trigeminus neuralgia, chemotherapy induced polyneuropathy, traumatic neuropathies, compression neuropathies, and infectious neuropathies in remission, according to the disclosure.

Abstract: The invention relates to an implantable device suitable for being fixed in a fixation position to a wall of a patient's stomach, the implantable device being accommodated in the stomach when the implantable device is in the fixation position, the implantable device being characterised in that it comprises a reserve of an active substance and an injector suitable for administering the active substance to the patient.

Abstract: The instant invention relates to new film-forming compositions based on starchy material, comprising isosorbide. The instant invention also relates to products made from the film-forming compositions of the invention, in particular hard and soft capsules shells, and to methods for the manufacture of such products.

Abstract: Aspects of the present disclosure include compositions having a plurality of individual polymeric nanowires. Individual polymeric nanowires according to embodiments include a bioactive compound. Methods for preparing and methods for administering the subject compositions of individual polymeric nanowires to a subject are also described. Kits having one or more components for practicing the subject methods are also provided.

Abstract: An emulsion comprising a continuous aqueous phase and a dispersed fatty phase in the form of drops, or conversely, wherein the drops comprise a shell formed of at least one anionic polymer comprising at least one carboxylic acid function and at least one cationic polymer comprising at least two amine functional groups, wherein the quantity of amine functional groups provided by the cationic polymer in the fatty phase is between 0.2 ?mol and 10.5 ?mol per gram of fatty phase.

Abstract: The invention relates to oil-in-water emulsion in which specific oils (e.g., lauric oils) are used in the oil phase while surprisingly maintaining excellent transparency. In one aspect, said emulsions comprise fatty acid in oil phase. In a separate co-pending application, the invention comprises an energy efficient process for making said fatty acid containing transparent nanoemulsions.

Abstract: The present disclosure is directed to a method of treating prediabetes or type 1 or type 2 diabetes mellitus comprising administering to a subject in need thereof an effective amount of imeglimin, wherein the subject has chronic kidney disease.

Abstract: Provided herein are constructs of micro-aggregate multicellular, minimally polarized grafts containing Leucine-rich repeat-containing G-protein coupled Receptor (LGR) expressing cells for wound therapy applications, tissue engineering, cell therapy applications, regenerative medicine applications, medical/therapeutic applications, tissue healing applications, immune therapy applications, and tissue transplant therapy applications which preferably are associated with a delivery vector/substrate/support/scaffold for direct application.

Abstract: The present disclosure provides topical compositions of rofecoxib and methods of making said compositions. The present disclosure also provides methods of using topical compositions of rofecoxib to treat inflammation.

Abstract: The present invention relates to a composition, preferably a cosmetic composition, comprising: (a) at least one oil; (b) at least one polyglyceryl fatty acid ester, preferably with a polyglyceryl moiety derived from 2 to 6 glycerins; (c) at least one compound selected from the group consisting of resorcinol and resorcinol derivatives; and (d) water. The composition according to the present invention can be in the form of a nano- or micro-emulsion, or can have a lamellar structure or a lamellar phase, with better transparency and stability.

Abstract: A facility for industrial drying and/or encapsulation of thermolabile substances comprising at least one injection unit (1) wherein the thermolabile substance is introduced, an encapsulating material when the facility is used to encapsulate, a solvent, additives and an injection gas flow for obtaining droplets from the thermolabile substance. It further comprises a drying unit (2) through which the droplets and a drying gas are introduced for evaporating the solvent and comprises a collection unit (3) configured to separate the microcapsules generated from the drying gas and which is selected from a cartridge filter collector, a cyclone collector or a combination of the two. It also describes a method for the industrial encapsulation of thermolabile substances which is carried out at the proposed facility.